San Francisco startup Structure Therapeutics can be engaged on an oral, once-everyday GLP-1 drug called GSBR-1290—the drug surpassed Wall Street’s expectations in June any time a mid-phase study confirmed average weight loss of about six% and it programs to start One more mid-phase demo towards the tip of the yr—that founder and CEO Raymond S